EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Curvebeam Ai Ltd (CVB) fair value: what the stock is really worth

We calculate from audited financials what Curvebeam Ai Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 12, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · AU · ISIN AU0000289761

CA Curvebeam Ai Ltd logo Thin data Jul 12, 2026

Curvebeam Ai Ltd

CVB · AU

Weak valuationQuality is weak on top of the rich price.

!Fair value A$0.0192 · Overvalued (−23%)
!Quality 37/100
!Mixed Growth (revenue YoY +85.3 %/yr)
!Loss-making · -133.1% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/10)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 2 out of 100
!Weak on future: 6 out of 100
Watch Curvebeam Ai Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.5000 A$0.0160 Fair Value A$0.0192 Aug 2023 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

37‑month range A$0.0160 – A$0.5000 · fair‑value band A$0.0178 – A$0.0221 · the A$0.0250 price screens above the A$0.0192 fair value. Dashed = 300-day average. As of Jul 12, 2026.

Follow Curvebeam Ai in your weekly email

Every Wednesday you see whether Curvebeam Ai is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and Australia.

Show more

CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and Australia. The company offers HiRise for bilateral weight bearing CT imaging; LineUP, a bilateral, weight bearing CT imaging of the knees and lower extremities for orthpedic practices; pedCAT Premium and pedCAT for imaging of the foot and ankle; InReach, a point-of-care extremity CT imaging which assess the distal extremities with 3D clarity at a fraction of the dose; and CubeVue Software visualization tools. It also provides software CurveBeam AI Autometrics for automatically segment foot and ankle datasets; Axiometrics, provides a semi-automatic measurement of the axes of rotation of the hip, femur, knee, and ankle; and TALAS, a measurement tool that semi-automatically calculate hindfoot alignment based on reproducible three-dimensional anatomical landmarks. In addition, the company offers custom web-based cloud platform; and OSSView. The company was incorporated in 2009 and is headquartered in Hatfield, Pennsylvania.

Stock analysis

Curvebeam Ai Ltd (CVB) currently trades at A$0.0250, while our model-based Fair Value estimate is A$0.0192, implying the stock looks roughly 30.2% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 85/100, which puts the evidence level at low.

Scenario range: A$0.0178 (bear) to A$0.0221 (bull), the price of A$0.0250 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Curvebeam Ai Ltd reported revenue of A$12.1M in FY2025 versus A$7.2M in FY2021, a compound +13.9%/yr. Reported net income was −A$16.8M in FY2025.

Key figures

Market cap A$9.7M (≈ $6.8M) · P/S ratio 0.68 · EPS (TTM) A$−0.0400 · Net margin −139% · Return on equity −41.8% · Return on assets (EBIT) −49.6% · Operating margin −181% · Revenue (TTM) A$12.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 56% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −23%, CVB screens richer than that median.

Fair Value models

Bear A$0.0178 Fair Value A$0.0192 Bull A$0.0221
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) A$0.0400 A$0.0500 A$0.0700 54
All 1 models by family
Asset-Based
NCAV (Graham) A$0.0400 A$0.0500 A$0.0700 54

Open the full fair value analysis →

Notify me when CVB reaches fair value

Put CVB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 36 · Market factors (momentum, volatility) 8

Profitability 4
Margins and returns on capital today
Quality Growth 84
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 55
Balance sheet, leverage, solvency risk
Investment 89
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 15
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 13
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−105.9% (2021) → −139.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CVB screens 30% overvalued. Compare with Abbott Laboratories, →

Compare Curvebeam Ai Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −23% · Below median
Profitability
Return on assets −14% · Bottom 25%
Net margin (TTM) −133% · Bottom 25%
Operating margin (TTM) −181% · Bottom 25%
Growth and dividend
Revenue growth 1% · Below median
Balance sheet
Debt / equity 0.41× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.19× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 0.56× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)2 · sector 10
FUTURE (revenue growth)6 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)79 · sector 97
DIVIDEND (yield)0 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.07 $74.79 −26%
Medtronic plc MDT $89.30 $65.57 −27%
Stryker Corporation SYK $269.75 $296.73 +10%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Curvebeam Ai Ltd · Fair Value
A$0.0192 −30%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Curvebeam Ai Ltd Fair Value". https://www.fairvalue-calculator.com/stock/CVB

Frequently asked questions

Is Curvebeam Ai Ltd (CVB) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of A$0.0192 versus a price of A$0.0250, about −23% upside (overvalued).
What is the fair value of CVB?
Our model-based fair value for Curvebeam Ai Ltd is A$0.0192 (as of Jul 12, 2026), built from audited fundamentals. The current price: A$0.0250.
What is the quality score of CVB?
Curvebeam Ai Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Curvebeam Ai Ltd (CVB)?
Our model-based price target is the fair value of A$0.0192 (as of Jul 12, 2026) from 1 valuation models. Cautious scenario A$0.0178, optimistic scenario A$0.0221. It is a calculation from audited fundamentals, not an analyst target.
What is the Curvebeam Ai Ltd stock forecast for 2026?
Our models put fair value at A$0.0192, about −23% upside versus a price of A$0.0250 (overvalued). Cautious scenario A$0.0178, optimistic scenario A$0.0221. The calculation is refreshed regularly with new filings.
What is the revenue of Curvebeam Ai Ltd (CVB)?
Curvebeam Ai Ltd reported trailing-twelve-month revenue of about A$12.2M (latest available figure, as of Jul 12, 2026).
What is the intrinsic value of Curvebeam Ai Ltd (CVB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Curvebeam Ai Ltd it is A$0.0192 per share (as of Jul 12, 2026), against a price of A$0.0250. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Curvebeam Ai Ltd stock overvalued or undervalued in 2026?
As of Jul 12, 2026, CVB trades above its calculated fair value: price A$0.0250, fair value A$0.0192, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CVB?
No. The price is what the market pays today (A$0.0250); the fair value is what the company's own numbers justify (A$0.0192). For Curvebeam Ai Ltd the two are A$0.0058 per share apart. That gap is exactly why we show both numbers side by side.
How much is Curvebeam Ai Ltd worth?
The market values Curvebeam Ai Ltd at about A$9.7M (market capitalisation, as of Jul 12, 2026). Per share that is A$0.0250; our models calculate a fair value of A$0.0192 per share.
What do the bullish and bearish scenarios say about CVB?
Our models span a range for Curvebeam Ai Ltd: cautious scenario A$0.0178, base A$0.0192, optimistic A$0.0221 per share (as of Jul 12, 2026, price A$0.0250). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Curvebeam Ai Ltd (CVB)?
Balance-sheet figures for Curvebeam Ai Ltd (as of Jul 12, 2026): return on equity −41.8%, debt of 0.41 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is CVB from its 52-week high?
Curvebeam Ai Ltd trades at A$0.0250, about 77% below its 52-week high of A$0.1100 and 56% above the low of A$0.0160 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0192 is for.
Which stocks are comparable to Curvebeam Ai Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Curvebeam Ai Ltd stock attractive at the current price?
The data as of Jul 12, 2026: price A$0.0250, calculated fair value A$0.0192 (−23%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CVB calculated?
We run Curvebeam Ai Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0192, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Curvebeam Ai Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Curvebeam Ai Ltd (CVB)?
The closing price on Sep 24, 2026 was A$0.0250. Our model-based fair value is A$0.0192, about −23% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Curvebeam Ai Ltd right now?
The price sits above even our optimistic bull case (A$0.0221). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Curvebeam Ai Ltd

How large is the market capitalisation of Curvebeam Ai Ltd (CVB)?
The market capitalisation of Curvebeam Ai Ltd is A$9.7M (≈ $6.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Curvebeam Ai Ltd (CVB)?
The price-to-sales ratio of Curvebeam Ai Ltd is 0.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Curvebeam Ai Ltd (CVB)?
Earnings per share at Curvebeam Ai Ltd are A$−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Curvebeam Ai Ltd (CVB)?
The net margin of Curvebeam Ai Ltd is −139% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Curvebeam Ai Ltd (CVB)?
The return on equity (ROE) of Curvebeam Ai Ltd is −41.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Curvebeam Ai Ltd (CVB)?
On an EBIT basis the return on assets of Curvebeam Ai Ltd is −49.6% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Curvebeam Ai Ltd (CVB)?
The operating margin of Curvebeam Ai Ltd is −181% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Curvebeam Ai Ltd (CVB)?
Revenue at Curvebeam Ai Ltd is growing +1.1% versus a year earlier (3y avg +93.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Curvebeam Ai Ltd (CVB) generate?
The free cash flow of Curvebeam Ai Ltd is −A$22.2M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Curvebeam Ai Ltd (CVB) carry?
The net debt of Curvebeam Ai Ltd is A$8.6M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Curvebeam Ai Ltd in the live analysis

One click puts Curvebeam Ai Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.